Purpose of review Prevention of coronary artery disease (CAD) is an appropriate goal for the 21st century. Randomized clinical studies consistently show a 30-40% reduction in mortality and morbidity by modifying known risk factors. However, genetic risk, estimated to account for 40-60% of susceptibility to CAD, has until recently been unknown. Comprehensive prevention will require knowledge of both.
INTRODUCTION
Coronary artery disease (CAD), despite the progress, remains the number one killer in the world. Prevention of CAD is felt to be an appropriate goal and many claim it should happen in the 21st century. It is well known that coronary artery disease and its sequelae (e.g. myocardial infarction) are in part due to inherited predisposition. Estimates have placed genetic predisposition to account for 40-60% of susceptibility to CAD [1] . CAD is preventable by randomized clinical studies [2, 3] , which consistently show a 30-40% reduction in mortality and morbidity by modifying the known risk factors, namely cholesterol and hypertension. It has been known for years that blood levels of low density lipoprotein (LDL) are in large part (70%) under genetic regulation and the blood level of HDL is over 80% genetically regulated [4 & ]. Similarly, it is expected that genetics play a role in hypertension [5] . It has been known for some time that a family history of heart disease adds to the risk over and above that of conventional risk factors. We know now that many genetic risk variants act independently of known risk factors. It is evident from the results of the Genome Wide Association Studies (GWAS) that prevention of CAD will require modifying genetic risk. The 21st century has accepted the challenge and within its first decade has identified a significant proportion of the genetic risk variants responsible for many diseases, including CAD.
THE GOLDEN AGE OF SINGLE-GENE DISORDERS
The genetic revolution for single-gene disorders has over the past two decades identified the genes responsible for over 2000 of the estimated 6000 single-gene disorders [6] . These disorders have sustained a major focus for genetic research and continue to enrich our understanding of the pathophysiology of these diseases, with implications for improving the management of others. These rare disorders (<0.1% of the population) depend on phenotyping pedigrees having individuals affected with the disease. A few hundred markers are adequate to map the genome for these diseases and such markers became more freely available in the 1980s. In some cases, such as glycogen storage disease, it has also led to a treatment [7] . In others, effective therapy is yet to be discovered. Genetic counselling is required for these diseases to allay the anxiety and help in securing proper testing and management. It is also cost-effective to identify individuals with the gene requiring follow-up procedures, as opposed to those without the gene, who can be relieved of the anxiety and the need for repeated procedures. It must not be underestimated that each time a gene responsible for a rare disease is identified it provides permanent unchanging information about that DNA region.
It was evident in the 1990s that common diseases, in contrast to single-gene disorders, are due to more common genes and have their genetic predisposition transmitted by multiple genes, each gene with only minimal to moderate increased risk for the disease. To detect these genes, analysis of pedigrees with a few hundred DNA markers would not have the resolution. It would require thousands of DNA markers and thousands of unrelated individuals analysed by a different method referred to as the casecontrol association study. The multiple DNA markers required by this approach were made possible by the HapMap Project, as indicated in the next section.
THE HAPMAP PROJECT AND SINGLE NUCLEOTIDE POLYMORPHISMS
It was recently recognized that the DNA sequence is essentially identical across 99.5% of all human genomes [8] . This is a very important and fundamental fact, with the corollary being that human genetic variation is due to a half of 1% of the DNA sequence. These unique sequences take on two forms, namely variation in the number of copies of large chunks of DNA, referred to as copy number variation [9 & ], and the variation due to single nucleotides. Based on current knowledge, more than 80% of human variation is due to unique single nucleotides [10] . They are referred to as single nucleotide polymorphisms (SNPs), of which each human genome has approximately 3 million. However, although the biodiversity of SNPs within any individual is limited to 3 million SNPs, they are selected from over 29 million SNPs available in the general population. The HapMap Project [11] annotated 1 million of these SNPs to their chromosomal location and provided the DNA markers necessary to map susceptibility to common polygenic disorders. This was followed by the 1000 Genome Project, which annotated the chromosomal location of over 29 million SNPs [12] .
THE GENOME WIDE ASSOCIATION STUDIES
The HapMap Project enabling the annotation of SNPs by the HapMap Project and more recently the 1000 Genome Project made it possible to genotype up to 1 million SNPs selected to span the genome. The GWAS to map the location of risk variants is unbiased and does not preselect any one marker to be associated with the disease prior to genotyping. The basis of GWAS is very simple. One compares the frequency of these SNPs as DNA markers in cases with that of their frequency in controls. A greater frequency of the SNP in cases indicates the marker is in close proximity to a genetic risk variant for the disease. It is also required that DNA markers showing a significant association in the discovery population would be analysed for confirmation in an independent population. This made it possible to map the chromosomal location of risk variants associated with disease. The results of the GWAS over a very short time have been remarkable, identifying over 1100 risk variants affecting over 160 diseases (http://www.genome. gov/gwastudies/).
MULTIPLE GENETIC RISK VARIANTS HAVE BEEN RELIABLY CONFIRMED TO PREDISPOSE TO CORONARY ARTERY DISEASE
It is only 6 years since the GWAS technology (2005) became available and 5 years since the first genetic
KEY POINTS
Identification of 36 genetic risk variants for coronary artery disease (CAD) will markedly facilitate prevention of this disease.
The mystery of genetic predisposition for CAD and other diseases is being rapidly unravelled.
The technology to genetically screen for CAD is here, as are many of the genes, but how it will change management is yet to be determined.
The finding of multiple genetic risk factors, independent of conventional risk factors, provides ample evidence of molecular pathways contributing to atherosclerosis yet to be discovered.
The results of Genome Wide Association Studies have opened new areas of research in CAD and the potential for novel drugs, as well as earlier detection and prevention.
risk variant for CAD was identified [13 & ,14] . In this short interval, 36 genetic risk variants for CAD have been identified and reliably confirmed (Table 1) [15, 33] , Chinese [34] , Korean [35] , Japanese [36] , Indian [37] and Pakistani ancestry [38] , but appears not to be a risk factor in Africans [39] . Shortly following this, 11 more variants from several investigators were confirmed by GWAS to be associated with risk for CAD [15, 16, 19, 20, [23] [24] [25] . Realizing the need for larger sample sizes than initially expected, 14 centres performing GWAS combined their resources to form an international consortium dedicated to genetics of CAD, referred to as Coronary Artery Disease Genome wide Replication and Meta-Analysis, with a discovery population of 87 000 and a replication population of 56 000 [40] . This is the largest collaboration ever in cardiology, costing over US$ 200 million, dedicated to pursuing genes predisposing to CAD. Utilizing the 1 million SNP array, they confirmed 10 of the 12 previous risk variants (Table 1) and 40 473 controls) . In addition to replication in independent samples, most studies performed meta-analysis of the joint populations, which also showed genome-wide significance. In the opinion of some statisticians [41] , genome-wide significance from joint meta-analysis is more powerful than replication in an independent population. As remarked in a recent study, the chance of even one of the 36 risk variants being a false positive is highly unlikely [42] .
GENETIC RISK ACROSS ANCESTRAL GROUPS
Unfortunately, information is incomplete on the risk variants for CAD as to whether they apply across ancestral groups. Of the five genetic risk variants discovered by the C4D group [ [34] , Korean [35] , Japanese [36] and Pakistani [38] ancestry, but is not a risk factor in Africans [39] . Although it is likely most variants will apply to all ancestral groups, it must be determined for each of them. This is on the basis of the fact that more of the genetic differences exist within ancestral groups than between them [43] .
COLLECTIVE INSIGHT AND ADVANTAGES OF GENETIC RISK VARIANTS ASSOCIATED WITH CORONARY ARTERY DISEASE
Although very little is known of the mechanisms whereby the risk variants induce risk, they have several features in common which are likely to also characterize variants yet to be identified. First, the risk variants for CAD are indeed very common, varying in frequency from 10 to 87% of the population. Second, over two-thirds of the genetic risk variants mediate their risk through unknown factors. Third, the increased relative risk of each variant for CAD is minimal, varying from 6 to 17%. Fourth, most genetic variants exhibit higher risk for early-onset than for late-onset CAD. Fifth, most of the genetic risk variants for CAD are located in DNA sequences that do not code for protein. This would imply that most of these polymorphisms exert their effect through regulation of protein expression. Sixth, DNA variants do not change during one's lifetime and neither do they change with age, meals, drugs or other environmental changes, so detection on one occasion is adequate. Thus, being genotyped at birth is adequate for a lifetime.
In Table 1 , it is worth noting that 10 of the risk variants (1p13, 1q41, 10q11, 1p32, 19p13, 1p32 , 6p21, 7q22, 10q24 and 5p13) have a mean frequency in the population of at least 75%. The next most common risk variants, of which there are eight, have a mean frequency in the population of at least 50% (6p23, 5q31, 6q23, 7q32, 8q24, 15q25, 17p11, 17q21). Seven of the risk variants (SORT1, PCSK9, LPA, ZNF259/APOA5, TRIB1, APOE, ABCG8, and LDLR) appear to mediate their risk through cholesterol. Two of the variants, CYP17A1 and SH2B3, mediate their risk through hypertension. The blood group ABO locus (9q34) is the only one so far proven to be associated with myocardial infarction and mediates its risk through increased thrombosis. The remainder of the risk variants has been shown through logistic regression analysis to mediate their risk independently of known risk factors such as lipids, hypertension, diabetes and smoking. Thus, while the effect of each genetic risk variant is small, the frequency in the population is extremely common and provides a robust platform for the ultimate discovery of their function and the molecular pathways mediating risk.
CONCLUSION
The role of genetic screening for CAD, while on the cusp, is still premature. If one waits until a new therapy is available to treat one or more of the new genetic risk variants then it is likely to be several years. It was decades between the appreciation of cholesterol as a risk factor and the development of specific therapy. We now know from the results of GWAS that comprehensive prevention of CAD must include preventing the effect of independent genetic risk factors. Thus, a major research thrust is to identify the mechanisms whereby new genetic risk variants contribute to the pathogenesis of CAD. Development of therapies to modify these new risk factors may well be the most important contribution from GWAS. There has been inadequate time to pursue the functions of genetic risk variants. 9p21, of which the most is known, has been shown to act on atherosclerosis and not myocardial infarction [44, 45] , but there remains controversy as to whether 9p21 predicts severity of CAD [36, 44, 45] . In early-onset CAD, the 9p21 locus carries a 50% increased risk in heterozygotes and a two-fold increased risk in homozygotes [13 & ,21 & ], which is equivalent to the two-fold increased risk of a current smoker [46] and the 40% increased risk of a 10 mm increase in blood pressure [47] or the 30% increased risk associated with a standard deviation increase in low density lipoprotein-cholesterol (LDL-C) or decrease in high density lipoprotein-cholesterol [48] .
Despite these findings, Paynter et al. [49] , using the technique of risk allele counting, found that the addition of 9p21 to conventional risk factors did not improve risk prediction. In contrast, Davies et al. [50] , assessing a weighed genetic risk score using logistic regression, showed the effect of combining 9p21 with 11 other genetic variants significantly improved risk prediction; however, the absolute increase was modest. Talmud et al. [51] in a longitudinal study of a population in the United Kingdom showed that 9p21 had modest effects but did reclassify a significant number of individuals into different risk categories. A recent study by Dutta et al. [52] found that adding 9p21 to the Framingham risk score improved clinical targeting of elderly patients, between ages 71 and 80 years. The role of genetic screening will ultimately depend on whether the results will alter the management of a patient with CAD. The technological barrier has been removed as it is currently possible to genotype the DNA of a blood sample or saliva for hundreds of genotypes on a single microarray within 60 min with an interpretable display.
How do these variants rank in terms of their risk? It is important to recognize that 50% of the 36 variants occur in more than 50% of the world's population. Thus, their population attributable risk is very significant. For example, the risk variant 9p21 is estimated to be homozygous in over 1 billion individuals and heterozygous in 2 billion more individuals. Current guidelines regarding the treatment of serum cholesterol depend on the number of additional risk factors for CAD present in that individual [53] . If there is no other risk factor, treatment is recommended only if the LDL-C is at least 160 mg/dl; if two risk factors, treat at 130 mg/dl and with several risk factors treat at 100 mg/dl. It is now well established for 9p21 and many other genetic risk variants that they are independent risk factors that occur in a large proportion of the world's population. Thus, an elevated LDL-C with no conventional risk factors but one or more genetic risk factors could categorize the individual into a higher risk category, resulting in more intensive treatment of LDL-C. This could be initiated before the development of specific drug therapy, but will of course require recommendation from authorities such as Adult Treatment Panel III.
